News
KPTIQ
0.022
+12.82%
0.003
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 1d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 2d ago
Why Sanmina Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Benzinga · 2d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 2d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 3d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 3d ago
Why Greenfire Resources Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Benzinga · 3d ago
Weekly Report: what happened at KPTI last week (1102-1106)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 5d ago
Karyopharm Therapeutics Inc. to be Delisted from Nasdaq Following Chapter 11 Bankruptcy Petitions
NASDAQ · 6d ago
Karyopharm Therapeutics Announces Nasdaq Delisting Following Bankruptcy Filing
TipRanks · 11/05 13:11
Karyopharm Therapeutic Common Shares To Be Suspended, Effective Nov. 11; To Trade On OTC Under KPTIQ Ticker
Benzinga · 11/05 12:29
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 11/04 21:05
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
PR Newswire · 11/04 14:01
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 11/03 21:05
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/03 17:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/03 12:05
Karyopharm Therapeutics Inc. Files for Chapter 11 Bankruptcy on November 2, 2026
NASDAQ · 11/03 11:51
Karyopharm Therapeutics Files for Chapter 11 Bankruptcy Protection
TipRanks · 11/03 11:28
More
Webull provides a variety of real-time KPTIQ stock news. You can receive the latest news about Karyopharm Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KPTIQ
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.